Meeting
2021 ASCO Annual Meeting
Comparison of therapy benefit from standard anti-HER2 directed approaches in metastatic breast cancer (MBC) between initially HER2-positive patients and patients initially HER2-negative with switch to HER2-positive.
Authors
Hans-Christian Kolberg
Marienhospital, Bottrop, Germany
Hans-Christian Kolberg , Özlem Yüksel , Peter A. Fasching , Sara Brucker , Hans Tesch , Diethelm Wallwiener , Lothar Haeberle , Markus Wallwiener , Peyman Hadji , Tanja N. Fehm , Wolfgang Janni , Diana Lüftner , Michael P Lux , Johannes Ettl , Andreas D. Hartkopf , Volkmar Müller , Florin-Andrei Taran , Erik Belleville , Alexander Hein , Andreas Schneeweiss
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Clinical Trial Registration Number
NCT02338167
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 1040)
DOI
10.1200/JCO.2021.39.15_suppl.1040
Abstract #
1040
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
First Author: Natália Polidorio
Poster
2021 ASCO Annual Meeting
Racial disparities in second-line (2L) treatment and overall survival among patients (pts) with hormone receptor positive HER2 negative (HR+HER2-) metastatic breast cancer (mBC) treated in routine practice.
First Author: Xiaoliang Wang
Poster
2020 ASCO Virtual Scientific Program
Value of clinical treatment score post-5 years (CTS5) for late relapse risk assessment in patients with early-stage HER2+ breast cancer (BC) in the north central cancer treatment group (NCCTG) N9831 (Alliance) trial.
First Author: Tanmayi Pai
Poster
2016 ASCO Annual Meeting
Treat ER+ight: Treatment of Canadian postmenopausal women with ER+ HER2- advanced breast cancer in the real-world setting with hormone therapy ± targeted therapy.
First Author: Nadia Califaretti